Soligenix Announces Publication of its Phase 2 Long-Term Follow-Up Results of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

PRINCETON, NJ – May 18, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials